BIOHAVEN LTD (BHVN) Stock Price, Quote, News and Overview
NYSE:BHVN - New York Stock Exchange, Inc. - VGG1110E1079 - Common Stock - Currency: USD
BHVN Quote, Performance and Key Statistics
29.86
-0.54 (-1.78%)
The current stock price of BHVN is 29.86 USD. In the past month the price decreased by -23.2%. In the past year, price decreased by -48.49%.
BHVN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About BHVN
Company Profile
Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 239 full-time employees. The company went IPO on 2022-09-23. The firm is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
Company Info
BIOHAVEN LTD
215 Church Street
New Haven CONNECTICUT 06510 US
CEO: Vlad Coric
Employees: 239
Company Website: https://www.biohaven.com/
Investor Relations: https://ir.biohaven.com/
Phone: 12034040410
BIOHAVEN LTD / BHVN FAQ
What is the stock price of BIOHAVEN LTD today?
The current stock price of BHVN is 29.86 USD. The price decreased by -1.78% in the last trading session.
What is the ticker symbol for BIOHAVEN LTD stock?
The exchange symbol of BIOHAVEN LTD is BHVN and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is BHVN stock listed?
BHVN stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for BIOHAVEN LTD stock?
22 analysts have analysed BHVN and the average price target is 66.06 USD. This implies a price increase of 121.25% is expected in the next year compared to the current price of 29.86. Check the BIOHAVEN LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOHAVEN LTD worth?
BIOHAVEN LTD (BHVN) has a market capitalization of 3.05B USD. This makes BHVN a Mid Cap stock.
How many employees does BIOHAVEN LTD have?
BIOHAVEN LTD (BHVN) currently has 239 employees.
What are the support and resistance levels for BIOHAVEN LTD (BHVN) stock?
BIOHAVEN LTD (BHVN) has a resistance level at 35.06. Check the full technical report for a detailed analysis of BHVN support and resistance levels.
Should I buy BIOHAVEN LTD (BHVN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BHVN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BHVN, evaluating the profitability, health, valuation and growth aspects
- BIOHAVEN LTD (BHVN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOHAVEN LTD (BHVN) Sales and EPS estimates to see what analysts future expectations are.
- BIOHAVEN LTD (BHVN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOHAVEN LTD (BHVN) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOHAVEN LTD (BHVN) Stock Chart to make your own analysis
- BIOHAVEN LTD (BHVN) Latest news and press-releases to stay up to date.
Does BIOHAVEN LTD (BHVN) stock pay dividends?
BHVN does not pay a dividend.
When does BIOHAVEN LTD (BHVN) report earnings?
BIOHAVEN LTD (BHVN) will report earnings on 2025-03-20, after the market close.
What is the Price/Earnings (PE) ratio of BIOHAVEN LTD (BHVN)?
BIOHAVEN LTD (BHVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.35).
What is the Short Interest ratio of BIOHAVEN LTD (BHVN) stock?
The outstanding short interest for BIOHAVEN LTD (BHVN) is 10.1% of its float. Check the ownership tab for more information on the BHVN short interest.
BHVN Technical Analysis
BHVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BHVN. The financial health of BHVN is average, but there are quite some concerns on its profitability.
BHVN Financial Highlights
Over the last trailing twelve months BHVN reported a non-GAAP Earnings per Share(EPS) of -9.35. The EPS decreased by -30.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -157.55% | ||
| ROE | -254.53% | ||
| Debt/Equity | 0 |
BHVN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to BHVN. The Buy consensus is the average rating of analysts ratings from 22 analysts.